Novo's Wegovy pill tracks 3,071 prescriptions in first days of launch

Core Insights - Novo Nordisk's Wegovy pill achieved 3,071 U.S. prescriptions within the first four days of its launch, indicating strong initial demand and interest from consumers [1] Company Performance - The rapid uptake of Wegovy suggests that Novo Nordisk may be on track to meet or exceed market expectations for this product [1] Market Reaction - Investors are closely monitoring the performance of Wegovy to assess its potential impact on Novo Nordisk's overall financial performance and market position [1]